The OS benefit was greater in patients with squamous cell carcinoma (HR 0.63 for squamous cell carcinoma and 0.78 for non-squamous non-small-cell carcinoma) and in those with lack of PD-L1 expression [23]. This evidence concerns the gene CD274 and squamous cell carcinoma.